How to Meet Regulatory Challenges in the New Year - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How to Meet Regulatory Challenges in the New Year
With 2007 projects wrapped up, or so we hope, forward-looking companies need to take their next step.


Pharmaceutical Technology
Volume 32, Issue 1

Although a RiskMAP's primary purpose is to communicate actions a company will take to minimize risk, an effective RiskMAP should do so while preserving the plan's benefits.

In March 2005, FDA issued the Guidance for Industry: Development and Use of Risk Minimization Action Plans. This guidance emphasizes the agency's shift in evaluation of products, from a safety and efficacy model, to a benefit versus risk model, ensuring that the benefits outweigh the risks. Some experts have applauded this change, stating that no effective product can be completely safe because potential for adverse reaction among consumers almost always exists —and that, therefore, measuring benefit to risk is more practical and useful. According to the guidance:

Benefit and risk information emerges continually throughout a product's life cycle (i.e., during the investigational and marketing phases) and can reflect the results of both labeled and off-label uses. Benefits and risks can result in a range of corresponding positive and negative effects on patient outcomes that may: (1) Be cosmetic, symptomatic, or curative; (2) Alter the course of the disease ; and (3) Affect mortality. Benefits and risks are difficult to quantify and compare because they may apply to different individuals and are usually measured and valued differently. (1)

Conclusion

The year 2008 will be challenging for pharmaceutical companies given the ever evolving requirements of the FDA. Although this fact should not come as a surprise to anyone in the industry, companies still need to be prepared and be able to move quickly so as not to compromise their businesses.

Patricia Santos-Serrão, RAC, is a regulatory advisor in the life-sciences practice at QUMAS,

Reference

1. FDA, Guidance for Industry: Development and Use of Risk Minimization Action Plans (Rockville, MD, March 2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here